New Haven R&D Tax Credit: Driving Innovation Forward

R&D Tax Credits for New Haven, Connecticut Businesses

New Haven, Connecticut, thrives in industries such as healthcare, education, biotechnology, and manufacturing. Top companies in the city include Yale New Haven Hospital, a major healthcare provider; Yale University, a leading educational and research institution; Alexion Pharmaceuticals, a prominent biotechnology company; Covidien, a key medical device manufacturer; and Southern Connecticut State University, a large educational institution. The R&D Tax Credit can benefit these industries by lowering tax burdens, encouraging innovation, and improving business performance.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 1000 Lafayette Boulevard, Bridgeport, Connecticut is less than 20 miles away from New Haven and provides R&D tax credit consulting and advisory services to New Haven and the surrounding areas such as: Bridgeport, Stamford, Hartford, Waterbury, and Norwalk.

If you have any questions or need further assistance, please call or email our local Connecticut Partner on (203) 680-9655.
Feel free to book a quick teleconference with one of our Connecticut R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

New Haven, Connecticut Patent of the Year – 2024/2025

Aeromics Inc. has been awarded the 2024/2025 Patent of the Year for breakthrough drug delivery targeting the blood-brain barrier. Their invention, detailed in U.S. Patent No. 11873266, titled ‘Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke’, uses antibodies engineered to bind selectively to aquaporin-4 – a key water channel protein in brain tissue.

This innovation enables precise transport of therapeutic agents across the blood-brain barrier, a major obstacle in treating neurological diseases. By leveraging antibodies that bind aquaporin-4 without disrupting its function, the technology delivers drugs directly to affected brain regions while minimizing systemic side effects.

The approach could transform treatment for conditions like Alzheimer’s, multiple sclerosis, and brain cancers, where traditional therapies often fail to penetrate brain defenses. Unlike many delivery methods that rely on broad disruption of the barrier, Aeromics’ platform offers targeted, controlled access with improved safety and efficiency.

This patent builds on years of research into membrane protein biology and therapeutic antibody design. It combines high-affinity binding with a modular delivery platform adaptable to various drugs.

Founded in Cleveland, Ohio, Aeromics has focused on translating academic discoveries into real-world treatments. This award-winning patent is a key milestone in their mission to unlock the blood-brain barrier and bring advanced therapies to patients with previously untreatable brain diseases.